科素亚与吲哒帕安治疗原发性高血压的疗效比较

目的：观察科素亚和吲哒帕安单用或合用对原发性高血压（EH）的降压作用和不良反应。方法：坐位舒张压（SDBP）在95～114mmHg的EH病人86例分为2组,科素亚组46例,眼科素亚50mg,qd（2周后如SDBP＞95mmHg时加服吲哒帕安2．5mg．qd）共6周;对照组40例．服吲哒帕安2．5mg,qd,连续用药6周。结果：两药合用降压疗效明显增强．不良反应少。结论：西药对EH有效,合用效佳,降压平稳且安全。     

海捷亚和卡托普利对高血压并发心衰的疗效比较

目的:观察血管紧张素Ⅱ受体阻滞剂海捷亚的降压疗效和对心功能的影响.方法:所有患者在观察期间原抗心衰药物(洋地黄制剂,利尿剂)不变.海捷亚组(40例)口服海捷亚每日1片,连用4周;卡托普利组(36例)口服卡托普利12 5～25 mg,每日2～3次,连用4周,用药前和用药后行超声心动图计算射血分数(EF)和E/A比值,评定用药前后心功能变化.结果:两组治疗4周后,心功能都有明显改善,海捷亚组总有效(显效 有效)率为82%,卡托普利组为66%,两组间相比,海捷亚组明显好于卡托普利组.结论:心衰患者使用海捷亚有利于缓解心衰症状,改善其收缩功能和舒张功能;其疗效优于卡托普利.     

氯沙坦与吲哒帕安治疗原发性高血压的疗效观察

氯沙坦(科素亚)是血管紧张素Ⅱ受体(AT_1)拮抗剂,是高血压药物治疗上的重要进展,其降压确实,副作用少,依从性好。吲哒帕安亦是新型利尿降压药。本文研究的目的是观察氯沙坦与吲哒帕安单用或合用的降压疗效。     

黄芪注射液合并小剂量尿激酶治疗不稳定性心绞痛56例

1996年5月～1997年3月,我们用黄芪注射液合并小剂量尿激酶治疗56例冠心病不稳定性心绞痛取得较好疗效,现报告如下。临床资料　106例住院患者,均符合冠心病不稳定性心绞痛的诊断标准(ＪＡｍＣｏｌｌＣａｒｄｉｏｌ1995;26∶313),且于入院前胸痛发作次数增多,而在入院前24ｈ内休息时亦有胸痛发作或近1周内胸痛发作间歇期<48ｈ。所有患者排除应用溶栓剂和抗凝剂的禁忌症,同时排除中重度充血性心衰、长期服用华法令(抗凝剂)及明显肝肾功能损害者。按入院的单日或双日随机分为黄芪组和对照组,前者56例(男33例,女23例),年龄37～69岁(平均48±11岁)…     

厄贝沙坦对高血压并发心力衰竭患者心功能的影响

目的 :观察血管紧张素Ⅱ受体阻滞剂厄贝沙坦的降压疗效和对心功能的影响。方法 :试验组 (n =4 0 )口服厄贝沙坦 15 0mg ,qd ,连用 4周 ;对照组 (n =36 )口服卡托普利 12 .5mg ,bid或tid ,连用 4周 ,用药期间仔细检查体格及心电图 ,给药前后行超声心动图计算射血分数 (EF)和E/A比值 ,评定心功能变化。结果 :试验组SBP和DBP都有明显降低 ,而对照组改变不明显 ,2组间比较差异非常显著 ;2组治疗后心功能都有明显改善 ,试验组总有效率为 80 % ,对照组为 6 1% ,2组比较差异有显著性 ;2组治疗后LVEF均升高 :试验组 0 .4 6± 0 .0 7vs 0 .4 1±0 .0 6 (P <0 .0 5 ) ,对照组 0 .4 2± 0 .0 6vs 0 .4 0± 0 .0 5 (P >0 .0 5 ) ;E/A比值升高 :试验组为 1.0 6± 0 .13vs 0 .5 8±0 .15 (P <0 .0 1) ,对照组 0 .76± 0 .12vs 0 .5 7± 0 .14 (P <0 .0 5 )。试验组好转更明显。结论 :厄贝沙坦有利于缓解心衰症状 ,改善其收缩功能和舒张功能 ;其疗效优于卡托普利。     

血塞通软胶囊辅助治疗急性脑梗死108例疗效观察

2002年10月～2004年3月,我们以血塞通软胶囊辅助治疗急性脑梗死108例,现将结果报告如下。     

辛伐他汀对高甘油三酯血症的作用

目的：观察辛代他汀对高甘油三酯血症的影响。方法：血清甘油三酯水平在2.24～6.78mmol／L（200—600mg／dL）的病人140例（男性82例．女住58例，年龄55±9岁）随机分为辛代他汀组和对照组。前者72例（男42例，女30例）．年龄56±10岁，每晚服用辛伐他汀20mg,连用8周，后者68例（男性40例，女性28例）年龄55±8岁，服用吉非诺齐300mg，tid，连用8周。结果：辛代他汀连用4～8WK明显降低血清高三酰甘油水平。亦降低血清LDLC水平，而且其作用明显强于吉非罗齐。结论：辛伐他汀对高三酰甘油血症有显效．特别适合于混合性高脂血症者。     

Effect of Xuesaitong Soft Capsule(血塞通软胶囊)on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction

Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊,XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group ( n = 96) and the treated group ( n = 108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrhe.ological indexes were measured before and after treatment. Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group (66.7%) was significantly higher than that in the control group (27.1%, P＜0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 inthem evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.     

硝苯吡啶对慢性肝炎、肝硬化的疗效观察

近年来的研究表明,慢性肝炎、肝硬化患者的肝细胞损伤与脂质过氧化物有关,一些天然的抗氧化剂如维生素E、辅酶Q_(10)、谷胱甘肽和合成的抗氧化剂开始在临床试用。作者考虑到钙通道阻滞剂硝吡苯吡啶(Nifedipine)即具有一定程度的抗氧化作用,又可能缓解门脉高压,故从1989年～1992年12月对照观察了硝苯吡啶对慢性肝炎(慢活肝、慢迁肝)及肝炎后肝硬化的治疗作用。 1 对象和方法 1.1 观察病例 慢性肝炎及肝硬化的诊断按1984年南宁会议修订的标准。下列情况除外:年龄>70岁;伴腹水及黄疸者;近期有上消化道出血;伴脑血管意外;血压<12.0/8.0kPa(90/60mmHg)。